Windsor Group LTD raised its position in AbbVie Inc. (NYSE:ABBV) by 1.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,512 shares of the company’s stock after acquiring an additional 170 shares during the quarter. Windsor Group LTD’s holdings in AbbVie were worth $1,769,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of ABBV. CVA Family Office LLC bought a new position in AbbVie in the third quarter valued at about $26,000. Harding Loevner LP lifted its holdings in AbbVie by 118.4% in the third quarter. Harding Loevner LP now owns 332 shares of the company’s stock valued at $29,000 after acquiring an additional 180 shares during the period. Joseph P. Lucia & Associates LLC bought a new position in AbbVie in the fourth quarter valued at about $29,000. James Investment Research Inc. bought a new position in AbbVie in the third quarter valued at about $32,000. Finally, Roble Belko & Company Inc increased its position in AbbVie by 70.8% in the third quarter. Roble Belko & Company Inc now owns 415 shares of the company’s stock worth $36,000 after buying an additional 172 shares in the last quarter. 67.49% of the stock is currently owned by institutional investors.
A number of brokerages have commented on ABBV. Royal Bank of Canada upped their price target on AbbVie from $129.00 to $135.00 and gave the stock an “outperform” rating in a research report on Thursday, February 4th. They noted that the move was a valuation call. Mizuho upped their price target on AbbVie from $117.00 to $126.00 and gave the stock a “buy” rating in a research report on Thursday, February 4th. They noted that the move was a valuation call. SVB Leerink upped their price target on AbbVie from $128.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, February 4th. BMO Capital Markets began coverage on AbbVie in a research report on Wednesday, November 18th. They issued an “outperform” rating and a $123.00 price target for the company. Finally, Sanford C. Bernstein assumed coverage on AbbVie in a research report on Tuesday, November 10th. They issued an “outperform” rating and a $120.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $114.39.
AbbVie stock traded down $0.62 during midday trading on Tuesday, reaching $106.44. 266,535 shares of the stock traded hands, compared to its average volume of 7,651,642. The stock’s fifty day moving average is $107.18 and its 200-day moving average is $97.93. AbbVie Inc. has a 12 month low of $62.55 and a 12 month high of $113.41. The stock has a market cap of $187.92 billion, a P/E ratio of 22.66, a PEG ratio of 1.54 and a beta of 0.84. The company has a quick ratio of 0.81, a current ratio of 0.95 and a debt-to-equity ratio of 5.38.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Tuesday, February 2nd. The company reported $2.92 EPS for the quarter, beating analysts’ consensus estimates of $2.85 by $0.07. AbbVie had a return on equity of 439.24% and a net margin of 18.16%. The company had revenue of $13.86 billion during the quarter, compared to analyst estimates of $13.70 billion. During the same period in the prior year, the company earned $2.21 earnings per share. The firm’s revenue was up 59.2% on a year-over-year basis. On average, equities analysts predict that AbbVie Inc. will post 10.48 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, May 14th. Investors of record on Thursday, April 15th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 4.89%. The ex-dividend date is Wednesday, April 14th. AbbVie’s payout ratio is presently 58.17%.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Further Reading: Initial Public Offering (IPO)
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.